Denali Therapeutics Inc. (DNLI) Stock Price & Analysis
Denali Therapeutics Inc. (DNLI) is trading at USD 19.32, up 0.13% today, as of October 29, 2026 at 19:58 UTC (US market open; quotes may be delayed), according to Nexqual market data.
DNLI last closed at USD 19.29; today's session has ranged USD 19.14–19.78 on volume of 878,259 shares. Market capitalization is $3.09B, with a 52-week range of USD 13.75–27.3 (NMS). Source: Nexqual, retrieved October 29, 2026 at 19:58 UTC.
Also available as compact Markdown for AI agents: nexqual.com/DNLI.md
Key facts (DNLI)
- Insider open-market sales, last ~7 months: 4 Form 4 filings, $435K; 2 not under a Rule 10b5-1 plan ($108K); 0 by opportunistic insiders, 2 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 1.95 on a 1–5 scale) (20 analysts), mean target USD 35.5 (range 23–42).
- Total return with dividends: 1Y +18.9% vs S&P 500 +13.1%; 5Y -60.0% vs S&P 500 +79.1%.
- Next earnings: 2026-11-03, EPS estimate USD -0.37, revenue estimate $22.9M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (DNLI)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $48.7M | $108M | $331M | $0K | $0K | — |
| Operating income | -$296M | -$341M | -$197M | -$487M | -$555M | -$543M |
| Net income | -$291M | -$326M | -$145M | -$423M | -$513M | -$511M |
| EPS (diluted) | -$2.39 | -$2.60 | -$1.06 | -$2.57 | -$2.97 | — |
| Free cash flow | -$220M | -$263M | -$371M | -$364M | -$422M | -$437M |
| Operating margin | -607.8% | -314.2% | -59.5% | — | — | — |
| Net margin | -597.2% | -300.6% | -43.9% | — | — | — |
| Revenue growth | -85.5% | +122.9% | +204.7% | -100.0% | — | — |
| Cash + short-term investments | $865M | $1.34B | $1.03B | $832M | $868M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (DNLI)
P/B 3.7x · FCF yield -14.17% · Earnings yield -16.57%
Insider sales (SEC Form 4, open-market, last ~7 months) (DNLI)
2 of 4 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-09-04 | Chin Peter Scott | Chief Medical Officer | 1,654 | $37K | 0.8% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-09-02 | Thornberry Nancy | Director | 11,439 | $262K | 36.8% | Yes (adopted June 3, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-09-01 | Schuth Alexander O. | COFO and Secretary | 2,768 | $65K | 0.3% | Yes (adopted March 27, 2026) | Routine (sold in Jan & Aug each year 2023–2025; this trade is outside those months) |
| 2026-08-11 | Schuth Alexander O. | COFO and Secretary | 2,857 | $72K | 0.4% | No | Routine (sold in Jan & Aug each year 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (DNLI)
Consensus Buy (mean 1.95 on a 1–5 scale), 20 analysts; mean target USD 35.5 (low 23, high 42).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-25 | B. Riley Securities | Target raised | Buy | $30 → $35 |
| 2026-08-07 | UBS | Target raised | Buy | $25 → $34 |
| 2026-07-23 | Morgan Stanley | Target raised | Overweight | $35 → $36 |
| 2026-07-16 | Deutsche Bank | Target raised | Buy | $31 → $35 |
Total return (dividends reinvested) (DNLI)
| 1Y (from 2025-10-29) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +18.9% | -60.0% |
| S&P 500 (SPY) | +13.1% | +79.1% |
| Per year | +18.9% | -16.7% |
| Volatility (annualized) | 55.3% | 58.0% |
| Max drawdown | -35.3% (Jul 2026→Oct 2026) | -78.6% (Nov 2021→Mar 2025) |
DNLI earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$0.68 | −$0.47 | Miss −44.7% | — |
| — | Quarter ended Mar 31, 2026 | −$0.69 | −$0.71 | Beat +2.8% | — |
| — | Quarter ended Dec 31, 2025 | −$0.73 | −$0.75 | Beat +2.7% | — |
| — | Quarter ended Sep 30, 2025 | −$0.74 | −$0.76 | Beat +2.6% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
DNLI recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Aug 6, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 6, 2026 | 8-K | Quarterly results |
| Aug 4, 2026 | Schedule 13G/A | BAILLIE GIFFORD & CO: 7.5% of shares, passive 5%+ holder (amended) |
| Jul 28, 2026 | 8-K | Completed an acquisition or sale of assets “On July 27, 2026, Denali Therapeutics Inc. (the "Company") completed the previously disclosed sale (the "Sale") of its Rare Pediatric Disease Priority Review Voucher (the "PRV") to a large pharmaceutical company. The Company received the PRV when AVLAYAHTM (tividenofusp alfa) was approved by the U.S. Food and Drug Administration for the treatment of Hunter syndrome (mucopolysaccharidosis type II; MPS II) in March 2026. The Sale was completed pursuant to the terms of an asset purchase agreement, dated June 12, 2026…” |
| Jul 8, 2026 | Schedule 13G/A | T. Rowe Price Investment Management, Inc.: 10.2% of shares, passive 5%+ holder (amended) |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
DNLI suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | TAKEDA PHARMACEUTICAL CO LTD (TAK) | “We have an active collaboration with Takeda Pharmaceutical Company Limited ("Takeda") for the development and commercialization of TAK-594/DNL593 (PTV:PGRN) for FTD-GRN.” |
| Partner | BIOGEN INC. (BIIB) | “Denali has an active collaboration with Biogen Inc.'s subsidiaries, Biogen MA Inc. ("BIMA") and Biogen International GmbH ("BIG") (BIMA and BIG, collectively, "Biogen") for the development and commercialization of BIIB122/DNL151.” |
| Partner | Sanofi (SNY) | “As part of our parallel development strategy, we have also developed peripherally-restricted RIPK1 inhibitor molecules, which are included as part of the collaboration agreement with Sanofi, described in more detail in "Business - Licenses and Collaborations" below.” |
| Partner | F-star | “In August 2016, we entered into a License and Collaboration Agreement ("F-star Collaboration Agreement") with F-star Gamma Limited ("F-star Gamma"), F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H ("F-star GmbH") and F-star Biotechnology Limited ("F-star Ltd") (collectively "F-star").” |
| Partner | Genentech | “In June 2016, we entered into an exclusive license agreement with Genentech, Inc. ("Genentech").” |
| Partner | F-star Gamma | “In August 2016, we entered into a License and Collaboration Agreement ("F-star Collaboration Agreement") with F-star Gamma Limited ("F-star Gamma"), F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H ("F-star GmbH") and F-star Biotechnology Limited ("F-star Ltd") (collectively "F-star").” |
| Partner | Biogen MA | “In August 2020, in connection with our collaboration with Biogen, we entered into a common stock purchase agreement with BIMA, pursuant to which we sold 13,310,243 shares of our common stock to BIMA for an aggregate purchase price of $465.0 million in September 2020.” |
| Partner | Royalty Pharma plc (RPRX) | “In December 2025, we entered into a royalty funding agreement with Royalty Pharma.” |
| Partner | F-star Biotechnology | “In August 2016, we entered into a License and Collaboration Agreement ("F-star Collaboration Agreement") with F-star Gamma Limited ("F-star Gamma"), F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H ("F-star GmbH") and F-star Biotechnology Limited ("F-star Ltd") (collectively "F-star").” |
| Partner | LLC and Leerink Partners | “In February 2025, we established a registered "at-the-market" facility for the potential future sale of up to $400.0 million of shares of common stock from time to time by entering into an equity distribution agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC as sales agents.” |
| Competitor | Eli Lilly (LLY) | “•Alzheimer's Disease: Treatments currently approved in some geographies for Alzheimer's Disease include the amyloid beta-directed antibody therapies ADUHELM (Biogen), LEQEMBI (Eisai/Biogen), and KISLUNA (Eli Lilly).” |
| Competitor | AbbVie (ABBV) | “Additionally, potentially disease modifying therapeutics are being developed by several large and specialty pharmaceutical and biotechnology companies, including Biogen/lonis, Arrowhead, Eli Lilly (including Prevail Therapeutics, its wholly owned subsidiary), Roche (including Genentech, its wholly owned subsidiary), AbbVie, Bristol Myers Squibb, Prothena, Regeneron, Alnylam, Eisai, and BioArctic in various stages …” |
Quoted from the company's 10-K filed Feb 26, 2026.
Companies that name DNLI in their SEC reports
| Relationship to DNLI | Company | Filing | Sentence |
|---|---|---|---|
| partner | Passage BIO, Inc. (PASG) | 10-K Mar 3, 2026 | “Denali Therapeutics Inc., in partnership with Takeda Pharmaceutical Company Limited, is conducting a Phase 1/2 clinical trial for their recombinant progranulin protein.” |
| partner | Sanofi (SNY) | 20-F Feb 17, 2026 | “•Denali Therapeutics Inc. (2018): collaboration agreement on the development of multiple molecules with the potential to treat” |
DNLI company outlook (results filed Aug 6, 2026)
- “Denali expects a Biologics License Application (BLA) submission and potential accelerated approval for zafinofusp alfa for Sanfilippo syndrome type A in 2027.”
- “Denali now expects results from the study in 2027, updated from its prior expectation of results by the end of 2026.”
- “Dosing of participants with late-onset Pompe disease began in the Phase 1 study of DNL952 in the second quarter of 2026, and initial clinical data are expected in 2027.”
- “Initial clinical biomarker data from the ongoing Phase 1b study of DNL628 in participants with Alzheimer's disease are expected in the first half of 2027. 2 DNL921 (ATV:Abeta) for Alzheimer's disease DNL921 is an investigational Antibody TransportVehicle ™ (ATV)-enabled antibody designed for systemic delivery across the blood-brain barrier to target amyloid plaques in Alzheimer's disease.”
Quoted word-for-word from the SEC 8-K results press release.
DNLI analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.37 | $-0.64 | +$0.28 | $22.9M | 17 |
| Next quarter (ends Dec 2026) | $-0.62 | $-0.68 | +$0.06 | $24.5M | 17 |
| Current fiscal year (ends Dec 2026) | $-2.23 | $-2.35 | +$0.12 | $50.7M | 17 |
| Next fiscal year (ends Dec 2027) | $-2.42 | $-2.49 | +$0.07 | $130.6M | 17 |
Key Statistics (as of October 29, 2026 at 19:58 UTC)
| Price | USD 19.32 |
|---|---|
| Change | ▲ 0.13% (up) |
| Previous Close | USD 19.29 |
| Open | USD 19.35 |
| Day Range | USD 19.14 – 19.78 |
| 52-Week Range | USD 13.75 – 27.3 |
| Volume | 878,259 shares |
| Market Cap | $3.09B |
| Exchange | NMS |
Technical Analysis (DNLI)
Nexqual's technical model rates DNLI "SELL" based on 2 bullish and 4 bearish signals across 128 daily candles, as of October 29, 2026 at 19:58 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 49.59 (neutral) |
| vs SMA50 | Below (USD 20.76) |
| MACD | -0.46 (negative) |
Analyst Ratings (DNLI)
Wall Street analysts rate DNLI "Buy" based on 20 analysts, with a mean price target of USD 35.5 (range USD 23–42), per Nexqual as of October 29, 2026 at 19:58 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 20 |
| Mean Target | USD 35.5 |
| High Target | USD 42 |
| Low Target | USD 23 |
| Buy / Hold / Sell | 19 / 1 / 0 |
Earnings (DNLI)
| Next Earnings Date | 2026-11-03 |
|---|---|
| EPS Estimate | USD -0.37 |
| Revenue Estimate | $22.90M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.68 vs est -0.47 ▼ miss |
| 2026-03-31 | USD -0.69 vs est -0.71 ▲ beat |
| 2025-12-31 | USD -0.73 vs est -0.75 ▲ beat |
| 2025-09-30 | USD -0.74 vs est -0.76 ▲ beat |
Source: Nexqual, October 29, 2026 at 19:58 UTC.
Financials & Fundamentals (DNLI)
| Total Revenue | $3.60M |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | -3601.30% |
| Profit Margin | +0.00% |
| ROE | -54.93% |
| Debt / Equity | 0.05 |
| Current Ratio | 8.37 |
| Total Cash | $710.47M |
| Total Debt | $37.69M |
Source: Nexqual, October 29, 2026 at 19:58 UTC.
Financial Health Score (DNLI)
Nexqual rates Denali Therapeutics Inc.'s overall financial health "Weak" across five dimensions, as of October 29, 2026 at 19:58 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $710M cash vs $38M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$413M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -61%, ROA -44.2% (last 4 quarters, SEC) |
Ownership (DNLI)
| Insider Ownership | +4.61% |
|---|---|
| Institutional Ownership | +101.33% |
| Shares Outstanding | 159.85M |
| Float | 155.10M |
| Short % of Float | +10.21% |
Source: Nexqual, October 29, 2026 at 19:58 UTC.
Leadership (DNLI)
Denali Therapeutics Inc. is led by Ryan J. Watts, Co-Founder, President, CEO & Director, per Nexqual as of October 29, 2026 at 19:58 UTC.
| Co-Founder, President, CEO & Director | Ryan J. Watts |
|---|---|
| Co-Founder, CFO, COO & Secretary | Alexander O. Schuth |
| Chief Scientific Officer | Joe Lewcock |
Major Backers & Investors (DNLI)
Notable institutional backers of Denali Therapeutics Inc. include T. Rowe Price, Baillie Gifford, Temasek Holdings (Private) Ltd, according to Nexqual as of October 29, 2026 at 19:58 UTC.
Active Investors
| Investor | Stake |
|---|---|
| T. Rowe Price | 10.12% |
| Baillie Gifford | 7.48% |
| Temasek Holdings (Private) Ltd | 4.39% |
| FMR, LLC | 2.84% |
| Goldman Sachs | 2.6% |
| SmallCap World Fund Inc | 1.56% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.77% |
| Vanguard Group | 7.98% |
| State Street | 4.41% |
| Geode Capital | 2.49% |
Source: Nexqual, October 29, 2026 at 19:58 UTC.
From Denali Therapeutics Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- We have invented, developed, and validated a proprietary technology, called the TransportVehicleTM ("TV"), to address the blood-brain barrier challenge and enable a new class of barrier-crossing therapeutics.
- We invented, developed, and continue to optimize a proprietary technology, called the TransportVehicleTM ("TV"), to deliver our large molecule biotherapeutic candidates to the brain after systemic administration.
- We have built a right-sized team in commercial and medical affairs to support tividenofusp alfa and additional ETV product launches.
Partnerships
- We have an active collaboration with Takeda Pharmaceutical Company Limited ("Takeda") for the development and commercialization of TAK-594/DNL593 (PTV:PGRN) for FTD-GRN.
- Denali has an active collaboration with Biogen Inc.'s subsidiaries, Biogen MA Inc. ("BIMA") and Biogen International GmbH ("BIG") (BIMA and BIG, collectively, "Biogen") for the development and commercialization of BIIB122/DNL151.
Legal & Regulatory Risks (Item 1A, quoted)
- We currently conduct clinical trials outside the United States, and the FDA, EMA and applicable foreign regulatory authorities may not accept data from such trials.
- We may be subject to claims challenging the inventorship of our intellectual property.
- We may be subject to claims that our employees, consultants, or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers.
- We currently and may in the future conduct clinical trials for our product candidates outside the United States, and the FDA, EMA, and applicable foreign regulatory authorities may not accept data from such trials.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ORKA | Oruka Therapeutics, Inc. | USD 96.23 | ▲ 0.27% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 317.34 | ▼ 0.45% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 9.6 | ▼ 35.21% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.46 | ▼ 0.98% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.55 | ▲ 0.03% |
| ABVX | Abivax SA | USD 89.21 | ▼ 0.7% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 19:58 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt